Key result
Selective serotonin reuptake inhibitor (SSRI) use was associated with an increased risk of subsequent diagnosis of irritable bowel syndrome (P<0.001).
Why the study?
Does selective serotonin reuptake inhibitor (SSRI) use increase the risk of subsequent irritable bowel syndrome?
Cohort (n=98,265)
Does selective serotonin reuptake inhibitor (SSRI) use increase the risk of subsequent irritable bowel syndrome?
Answers are grounded in this paper and cite their sources.
SSRI use is associated with an increased risk of subsequently developing irritable bowel syndrome in a Taiwanese population.
AIM: To investigate the relationship between selective serotonin reuptake inhibitor (SSRI) use and the subsequent development of irritable bowel syndrome (IBS). METHODS: This retrospective, observational, population-based cohort study collected data from Taiwan's National Health Insurance Research Database. A total of 19653 patients newly using SSRIs and 78612 patients not using SSRIs, matched by age and sex at a ratio of 1:4, were enrolled in the study from January 1, 2000 to December 31, 2010. The patients were followed until IBS diagnosis, withdrawal from the National Health Insurance system, or the end of 2011. We analyzed the effects of SSRIs on the risk of subsequent IBS using Cox proportional hazards regression models. CONCLUSION: SSRI users show an increased risk of subsequent diagnosis of IBS in Taiwan.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2017) conducted a cohort in Irritable bowel syndrome (n=98,265). Selective serotonin reuptake inhibitors (SSRIs) vs. No SSRI use was evaluated on Subsequent development of irritable bowel syndrome (IBS) (p=<0.001). Selective serotonin reuptake inhibitor (SSRI) use was associated with an increased risk of subsequent diagnosis of irritable bowel syndrome (P<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: